...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
【24h】

Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.

机译：荷兰脑膜炎球菌C血清群共轭疫苗接种计划的经济评估及其对决策的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The cost-effectiveness of one time vaccination of all persons aged 14 months to 18 years (catch-up programme) and of routine childhood immunisation at either ages 2+3+4 months, 5+6 months, or 14 months with a meningococcal C conjugate vaccine was estimated for The Netherlands, from a societal and a health care payer perspective. A decision analysis cohort model was employed (time horizon 77 years), direct and indirect costs (friction cost method) were considered and future costs and effects were discounted at 4%. The results showed that all vaccination options yield a substantial health gain and that the catch-up programme and routine vaccination at 14 months render favourable cost-effectiveness ratios: between about Euro 13,200 and Euro 17,700 per life year gained for the catch-up programme and between about Euro 2200 and Euro 2400 per life year gained for routine childhood vaccination at 14 months, depending on the perspective. In comparison to vaccination at 14 months, routine childhood vaccination during the first year of life is much less cost-effective: each additional life year gained costs approximately Euro 147,000 (2+3+4 months) or Euro 102,000 (5+6 months), from both perspectives. Additionally, inclusion of the likely herd immunity effect of the catch-up programme increases these incremental cost-effectiveness ratios. These results played a major role in the decision to add meningococcal C vaccination to the routine childhood immunisation schedule at 14 months and to implement a catch-up vaccination programme in The Netherlands in 2002.
机译：对年龄在14个月至18岁之间的所有人进行一次疫苗接种（追赶计划），以及在2 + 3 + 4个月，5 + 6个月或14个月时接受脑膜炎球菌C接种的常规儿童免疫接种的成本效益从社会和卫生保健付款人的角度估计了荷兰的结合疫苗。采用了决策分析队列模型（时间跨度为77年），考虑了直接和间接成本（摩擦成本法），并将未来成本和影响折现为4％。结果表明，所有的疫苗接种方案都能带来可观的健康收益，并且在14个月的时间里进行的追赶计划和常规疫苗接种具有良好的成本效益比：追赶计划每生命年可获得约13,200欧元至17,700欧元，以及在14个月的常规儿童期疫苗接种过程中，每个生命年可获得大约2200欧元至2400欧元的收益，具体视情况而定。与14个月的疫苗接种相比，生命第一年的常规儿童期疫苗接种的成本效益要低得多：每增加一生命年，大约需要花费147,000欧元（2 + 3 + 4个月）或102,000欧元（5 + 6个月） ，从两个角度来看。此外，将赶超计划可能带来的群体免疫效应包括在内，可以增加这些增加的成本效益比。这些结果在决定将脑膜炎球菌C疫苗添加到常规的14个月儿童免疫接种计划以及2002年在荷兰实施追赶疫苗接种计划的决定中起着重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号